Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Oct 25,2023
Medicilon congratulated AnDiCon Biotech collaborated with Simcere Pharmaceuticals to accelerate the commercialization of a new generation of anti-influenza drug ADC189
On October 10, 2023, Simcere Pharmaceutical Group Ltd. (2096.HK) announced that they entered into a collaboration agreement with Jiaxing AnDiCon Biotech Co., Ltd. (AnDiCon) on the anti-influenza innovative drug ADC189.
More
Medicilon congratulated AnDiCon Biotech collaborated with Simcere Pharmaceuticals to accelerate the commercialization of a new generation of anti-influenza drug ADC189
Oct 25,2023
Successful registration of ABSL-2 laboratory! Medicilon becomes a one-stop biopharmaceutical preclinical CRO with both ABSL-2 and BSL-2 laboratories
On October 12, 2023, the ABSL-2 laboratory of Shanghai Medicilon Inc. (Medicilon) obtained the "Registration Certificate for Animal Pathogenic Microorganisms Laboratory in Pudong New Area, Shanghai" issued by the Shanghai Pudong New Area Agriculture and Rural Affairs Committee.
More
Successful registration of ABSL-2 laboratory! Medicilon becomes a one-stop biopharmaceutical preclinical CRO with both ABSL-2 and BSL-2 laboratories
Oct 17,2023
Medicilon was selected as "2023 Science and Technology Innovation Board Hard and Core Technology Leading Enterprise"
Shanghai Medicilon Inc (Medicilon) has been selected as a " 2023 Science and Technology Innovation Board Hard and Core Technology Leading Enterprise" based on its hard-core advantages in biopharmaceutical technology innovation over the years.
More
Medicilon was selected as "2023 Science and Technology Innovation Board Hard and Core Technology Leading Enterprise"
Sep 20,2023
Medicilon's Interview: See how Dr. Chen Chen from ABM Therapeutics crosses the blood-brain barrier
Shanghai Medicilon Inc. (Medicilon) has the honor to invite Dr. Chen Chen, Founder and Chairman of ABM Therapeutics, to discuss the unique technical advantages and R&D strategies of ABM Therapeutics in developing brain-targeted drugs, as well as the inner journey and profound insights.
More
Medicilon's Interview: See how Dr. Chen Chen from ABM Therapeutics crosses the blood-brain barrier
Aug 14,2023
Medicilon was selected into the SSE Science and Technology Innovation Board 100 Index, R&D intensity and revenue growth have been recognized
On August 7, 2023, the Shanghai Stock Exchange officially launched the SSE Science and Technology Innovation Board 100 Index. Shanghai Medicilon Inc. was selected as one of the SSE Science and Technology Innovation Board 100 Index.
More
Medicilon was selected into the SSE Science and Technology Innovation Board 100 Index, R&D intensity and revenue growth have been recognized
Jul 31,2023
Medicilon interview with Dr. Xin Dong - In the field of immunotherapy, where the fierce competition is in full swing, where does Neologics Bioscience come from?
Medicilon interviewed Dr. Xin Dong to get a glimpse of his profound insights in the field of immunotherapy, and "learn from the experience" to grow in the era of new drugs.
More
Medicilon interview with Dr. Xin Dong - In the field of immunotherapy, where the fierce competition is in full swing, where does Neologics Bioscience come from?
Jul 28,2023
Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together
On July 25, 2023, Fosun Health Capital established by Fosun Pharma（stock code:600196.SH), reached a strategic partnership with Medicilon（stock code: 688202.SH).
More
Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together
Jul 27,2023
The Medicilon DMPK team was praised again, and Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award
Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award the Medicilon DMPK team the "Best Partner Award" to express their gratitude and recognition.
More
The Medicilon DMPK team was praised again, and Dr. Yan Feng, CEO of Leading Tac Pharma, came to present the award
Jul 27,2023
Fudan University, School of Management "Science and Technology Entrepreneur Camp" entered Medicilon: "Hardcore Technology" as the background color, Adding "luster" to new drug research and development
On July 14, Professor Xiongwen Lu, Dean of the School of Management of Fudan University, led the professor group of Fudan School of Management and the students of the fifth phase of the Fudan Science and Technology Entrepreneur Camp into the Zhangjiang Park of Shanghai Medicilon Inc. (Medicilon) to conduct a site visit.
More
Fudan University, School of Management "Science and Technology Entrepreneur Camp" entered Medicilon: "Hardcore Technology" as the background color, Adding "luster" to new drug research and development
Jul 14,2023
Another honor! Medicilon won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023
The press conference released the most influential list of China's pharmaceutical industry in 2022-2023. Medicilon once again won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023 based on its comprehensive strength.
More
Another honor! Medicilon won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023
Jul 12,2023
Medicilon topped the "Top 10 Most Influential CRO Enterprises" in the 2023 China Biopharmaceutical Industry Value List
The 9th BIO-PHARM2023 and the 2023 China Biopharmaceutical Industry Value List Awards Ceremony were grandly opened in Suzhou. Medicilon was listed in the "Top 10 Most Influential CRO Enterprises".
More
Medicilon topped the "Top 10 Most Influential CRO Enterprises" in the 2023 China Biopharmaceutical Industry Value List
Jul 12,2023
Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and development of ophthalmic cell and gene drugs
Recently, Shanghai Medicilon Inc. (Medicilon) and EyeCure reached a strategic collaboration. The two parties will carry out comprehensive collaboration in the field of ophthalmic cell and gene therapy.
More
Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and development of ophthalmic cell and gene drugs
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->